{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011145","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.727414+00:00","generated_at":"2026-06-04T08:51:33.085206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sanara MedTech revenue up 42% to $65M in FY2023; net loss narrows to $4.4M","bullets":["FY2023 net revenue of $65.0M, up 42% from $45.8M in FY2022.","Q4 2023 record sales of $17.7M; net loss of $0.3M vs $4.2M loss in Q4 2022.","FY2023 net loss of $4.4M, improved from $8.1M loss in FY2022.","Adjusted EBITDA negative $0.3M for FY2023 vs negative $7.5M in prior year; Q4 breakeven.","Launched ALLOCYTE Plus and BIASURGE; signed exclusive license with Tufts University for peptide tech."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011145","json":"https://secwatch.observer/filing/0001493152-24-011145.json","markdown":"https://secwatch.observer/filing/0001493152-24-011145.md","text":"https://secwatch.observer/filing/0001493152-24-011145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315224011145/0001493152-24-011145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315224011145/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:51:33.085206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65176f09319295719ec0409b40b93c01972bcb4e","claim":"Sanara MedTech Inc. reported the quarter and year ended December 31, 2023 results: revenue $17.7 million, net income net loss of $0.3 million.","evidence_excerpt":"outcomes and reduce costs throughout the U.S.” Strategic and Operational Highlights in the Fourth Quarter 2023 ● In the fourth quarter 2023, the Company generated a record $17.7 million in sales, representing a ninth record revenue quarter for the Company. ● For the three months ended December 31, 2023, the Company had a net loss of $0.3 million, compared to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/714256/000149315224011145/0001493152-24-011145-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$17.7 million"},{"label":"Net income","value":"net loss of $0.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b7315136a9e1cfbc1af2b43b98b733825a20e968","claim":"Sanara MedTech Inc. reported the year ended December 31, 2023 results: revenue $65.0 million, net income net loss of $4.4 million.","evidence_excerpt":"For the year ended December 31, 2023, Sanara generated net revenues of $65.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/714256/000149315224011145/0001493152-24-011145-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$65.0 million"},{"label":"Net income","value":"net loss of $4.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}